New hope for hard-to-treat nose and throat cancer: targeted drug combo shows promise
NCT ID NCT07496190
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called becotatug vedotin in people with advanced nasopharyngeal cancer whose tumors didn't shrink enough after standard chemo-immunotherapy. About 59 adults will receive the drug during and after radiation therapy. The goal is to see if this approach can prevent the cancer from coming back or spreading.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCOREGIONALLY ADVANCED NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a baking soda rinse tame radiation mouth sores?
- New drug duo aims to keep advanced nasopharyngeal cancer in check
- New surveillance strategy aims to catch residual cancer early in High-Risk nasopharyngeal carcinoma
- New combo strategy aims to catch and remove leftover cancer after radiation
- New combo injection targets Hard-to-Treat head and neck tumors
- New risk model may personalize Post-Chemo decisions for nasopharyngeal cancer